Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study.

ABSTRACT:

Background

Chemoimmunotherapy has become one of the standard first-line treatment options for advanced non-small-cell lung cancer (NSCLC) across programmed death-ligand 1 (PD-L1) strata, yet outcomes in PD-L1-low/negative disease remain suboptimal. We evaluated whether the Lung Immune Prognostic Index (LIPI) at treatment initiation has prognostic value in this subgroup.

Patients and methods

We conducted a multicenter retrospective cohort study across nine Japanese hospitals (January 2016-September 2021). Clinical data, including results of pretreatment blood tests at first-line treatment initiation, were collected and used to categorize LIPI (good, intermediate, or poor). Endpoints were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier and log-rank test

SUBMITTER: Yoshimura A 

PROVIDER: S-EPMC12670098 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature